Results 221 to 230 of about 67,119 (304)

Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group. [PDF]

Clin Hematol Int
Chen W, Cai Z, Chim CS, Chng WJ, Du J, Fu C, Gao W, Hanamura I, Hou J, Huang JS, Ishida T, Li C, Liu A, Ptushkin V, Takezako N, Wong RSM, Yoon DH.   +16 more
europepmc   +1 more source

The Steroidal Profile Modulates Adaptive Immune Response and Prognosis in Adrenocortical Carcinoma: Analysis of TCR and BCR Repertoires

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT Adrenocortical carcinoma (ACC) is a rare and aggressive malignant neoplasm with limited therapeutic options and an often poor prognosis. A deeper understanding of its interaction with the immune system is essential for the advancement of personalized treatment strategies, particularly in light of the tumor heterogeneity of hormone production ...
Jean Silva de Souza Resende, Igor Samesima Giner, João Carlos Degraf Muzzi, José Alexandre Marzagão Barbuto, Enzo Lalli, Mauro Antônio Alves Castro, Bonald Cavalcante de Figueiredo   +6 more
wiley   +1 more source

Awareness and Utilization of the Revised Second International Staging System (R2‐ISS) and 1q21 Gain/Amplification Testing: A Nationwide Web‐Based Survey of Hematologists in Japan

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT Background Although the multiple myeloma (MM) treatment landscape has significantly advanced, MM remains an incurable disease. Accurate risk stratification and its broad clinical implementation are essential for optimizing treatment strategies. International Staging System (ISS), its revised versions (R‐ISS and R2‐ISS), and cytogenetic testing
Nami Tagami, Heigoroh Shirai, Ichiro Hanamura   +2 more
wiley   +1 more source

Rapid Discovery of CD38 Inhibitor via DNA-Encoded Natural Product Library Screening. [PDF]

Molecules
Shi X, Liang Z, Meng W, Yang G, Yan L.
europepmc   +1 more source

Bone Marrow Failure Model Mimics Aplastic Anemia Patients: Single‐Cell Landscape of Immune Response Reveals Novel Mechanisms of Immune Imbalance in AA

Cancer Medicine, Volume 15, Issue 6, June 2026.
Single‐cell RNA‐seq is used in a mouse model of immune‐mediated bone marrow failure. Approach to platelets and mitochondrial data. Analysis of various immune cell landscapes, interactions and driving factors in BMF, involving platelets, CD4+ T Cells, CD8+ T Cells, macrophages, and mitochondrial energy metabolism pathways.
Shuai Tan, Fang Fang, Jing Sun, Yumeng Li, Yaochi Chen, Wanling Sun   +5 more
wiley   +1 more source

Clinical Characteristics, Treatment Patterns, and Prognosis of Central Nervous System Involvement in Multiple Myeloma: A Multicenter Retrospective Study From China

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT Background Central nervous system (CNS) involvement is a rare and aggressive complication of multiple myeloma (MM), with limited data on its clinical characteristics and prognosis. This multicenter study characterizes the largest Chinese cohort of MM patients with CNS involvement (MM‐CNS) to date.
Wenjing Li, Weiwei Tian, Jie Ma, Linyu Li, Zhihua Li, Jie Liu, Guorong Gao, Zhenfang Xi, Lan Zhang, Weihua Zhang, Lixiang Duan, Hui Geng, Jie Meng, Honghu Zhu, Wenming Chen, Wen Gao   +15 more
wiley   +1 more source

NAD⁺‒circadian rhythm coupling in dementia. [PDF]

Alzheimers Dement
Zhang SQ, Lee J, Pan JP, Enger R, Hrubos-Strøm H, Musiek ES, Fang EF, Le W.   +7 more
europepmc   +1 more source

Prognostic Value of Next‐Generation Flow Cytometry Versus Dual‐Tracer PET/CT for Minimal Residual Disease Assessment in Multiple Myeloma

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT To evaluate the comparative prognostic utility of next‐generation flow cytometry (NGF) and dual‐tracer PET/CT in measuring minimal residual disease (MRD), this prospective real‐world study enrolled 118 newly diagnosed multiple myeloma (NDMM) patients. Patients underwent post‐treatment assessment using NGF (sensitivity 10−5) and dual‐tracer PET/
Runfeng Zhang, Wenjia Zhu, Lili Cheng, Jianhua Du, Fujing Zhang, Qiao Yang, Huijuan Wang, Yun Leng, Miao Chen, Li Huo, Junling Zhuang   +10 more
wiley   +1 more source

A phase II study of daratumumab and ibrutinib for relapsed/refractory chronic lymphocytic leukemia. [PDF]

Blood Cancer J
Parrondo RD, Ailawadhi S, Knopf BR, Zimmerman A, Kasik CJ, Chapin D, Heslop K, Roy V, Paulus A, Chanan-Khan AA.   +9 more
europepmc   +1 more source

CD38 wt Allele [PDF]

, 2020
openaire   +1 more source